- Report
- March 2024
- 196 Pages
Global
From €3259EUR$3,374USD£2,789GBP
€3621EUR$3,749USD£3,099GBP
- Report
- April 2024
- 93 Pages
Global
From €5409EUR$5,600USD£4,628GBP
- Report
- January 2024
- 200 Pages
Global
From €4829EUR$5,000USD£4,132GBP
- Report
- April 2022
- 150 Pages
Global
From €5747EUR$5,950USD£4,918GBP
From €3380EUR$3,500USD£2,893GBP
- Report
- February 2024
- 191 Pages
Global
From €3477EUR$3,600USD£2,975GBP
The Implantable Cardiac Rhythm Management Device (CRM) market is a subset of the larger Cardiovascular Devices market. CRM devices are used to monitor and treat cardiac arrhythmias, or abnormal heart rhythms. These devices are implanted in the body and can detect and treat arrhythmias, as well as provide data to physicians for diagnosis and treatment. CRM devices include pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices.
CRM devices are used to treat a variety of cardiac conditions, including bradycardia, tachycardia, and atrial fibrillation. They are also used to monitor heart rate and rhythm, and to provide data to physicians for diagnosis and treatment.
Some of the major companies in the Implantable Cardiac Rhythm Management Device market include Medtronic, Abbott, Boston Scientific, Biotronik, and Sorin Group. Show Less Read more